Imexpharm Corporation (HOSE: IMP)

Market Cap	7.69T
Revenue (ttm)	2.08T
Net Income (ttm)	227.12B
Shares Out	154.01M
EPS (ttm)	1,474.62
PE Ratio	33.84
Forward PE	24.88
Dividend	454.55 (0.90%)
Ex-Dividend Date	Jul 11, 2024

Volume	105,900
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	23,682 - 56,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 17, 2024

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-histamines, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals. It is also involved in the import and export of medical equipment and supplies, chemicals, materials for ...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,415
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2023, Imexpharm's revenue was 1.99 trillion, an increase of 21.31% compared to the previous year's 1.64 trillion. Earnings were 254.62 billion, an increase of 38.50%.